We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+3.9%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$1.35B
AUM Growth
-$238M
Cap. Flow
-$201M
Cap. Flow %
-14.89%
Top 10 Hldgs %
64.03%
Holding
94
New
18
Increased
13
Reduced
24
Closed
26

Top Buys

Rank Stock Value
1
INZY
Inozyme Pharma
INZY
+$50.4M
2
CMPI
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
+$46.2M
3
AMGN icon
Amgen
AMGN
+$27.7M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$19.8M
5
NCNA
NuCana
NCNA
+$18.1M

Top Sells

Rank Stock Value
1
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$84.7M
2
GILD icon
Gilead Sciences
GILD
+$31M
3
CHRS icon
Coherus Oncology
CHRS
+$27.9M
4
AMRN
Amarin Corp
AMRN
+$24.2M
5
MRK icon
Merck
MRK
+$21.4M

Sector Composition

Rank Sector Weight
1 Healthcare 93.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
51
CALL
Moderna
MRNA
$22.1B
$3.54M 0.26%
+50,000
New +$3.49M
TCRR
52
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$3.52M 0.26%
+173,028
New +$3.04M
IMTX icon
53
Immatics
IMTX
$1.19B
$3.45M 0.26%
+325,527
New +$3.43M
LQDA icon
54
Liquidia Corp
LQDA
$7.72B
$3.34M 0.25%
679,400
-120,600
-15% -$698K
BCRX icon
55
BioCryst Pharmaceuticals
BCRX
$2.48B
$2.73M 0.2%
793,054
-564,794
-42% -$2.42M
QTTB icon
56
Q32 Bio
QTTB
$467M
$2.55M 0.19%
13,223
-5,920
-31% -$1.33M
KDMN
57
DELISTED
Kadmon Holdings, Inc.
KDMN
$2.47M 0.18%
629,923
-900,941
-59% -$3.78M
CGEN icon
58
Compugen
CGEN
$214M
$2.38M 0.18%
146,592
+43,005
+42% +$705K
ETTX
59
DELISTED
Entasis Therapeutics Holdings Inc.
ETTX
$2.06M 0.15%
1,012,408
-167,770
-14% -$479K
ACAD icon
60
Acadia Pharmaceuticals
ACAD
$4.45B
$2.02M 0.15%
+48,996
New +$2.12M
CALA
61
DELISTED
Calithera Biosciences, Inc
CALA
$1.7M 0.13%
24,665
-27,355
-53% -$2.39M
FATE icon
62
Fate Therapeutics
FATE
$270M
$1.65M 0.12%
+41,400
New +$1.45M
RGNX icon
63
Regenxbio
RGNX
$615M
$1.64M 0.12%
+59,507
New +$1.94M
SYBX
64
DELISTED
Synlogic
SYBX
$1.16M 0.09%
38,331
– –
SVRA icon
65
Savara
SVRA
$1.09B
$409K 0.03%
+375,591
New +$643K
PDSB icon
66
PDS Biotechnology
PDSB
$38.6M
$332K 0.02%
142,635
– –
AKBA icon
67
Akebia Therapeutics
AKBA
$341M
– –
-681,892
Closed -$9.26M
ALNY icon
68
CALL
Alnylam Pharmaceuticals
ALNY
$38.5B
– –
-150,000
Closed -$22.2M
AMGN icon
69
PUT
Amgen
AMGN
$212B
– –
-168,500
Closed -$39.7M
APLS
70
DELISTED
Apellis Pharmaceuticals
APLS
– –
-49,580
Closed -$1.62M
AXSM icon
71
Axsome Therapeutics
AXSM
$12.1B
– –
-86,978
Closed -$7.16M
BPMC
72
DELISTED
Blueprint Medicines
BPMC
– –
-94,891
Closed -$7.4M
GILD icon
73
Gilead Sciences
GILD
$167B
– –
-403,494
Closed -$31M
IMVT icon
74
Immunovant
IMVT
$7.99B
– –
-40,513
Closed -$987K
KALA icon
75
KALA BIO
KALA
$12.3M
– –
-203
Closed -$5.33M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q3 2020 Portfolio in Review

As of Q3 2020, Sofinnova Investments held 94 positions worth $1.35B, down 15% from $1.59B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Sofinnova Investments withdrew a net $201M in Q3 2020, closing 26 positions and reducing 24 holdings. Its most notable exit was Principia Biopharma Inc. Common Stock, an estimated $84.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 90% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Inozyme Pharma worth $53.3M.

  • Sofinnova Investments's largest Q3 2020 buy was Inozyme Pharma: 2,028,308 shares worth $53.3M.
  • Sofinnova Investments added most to BioMarin Pharmaceuticals in Q3 2020, an estimated $19.8M increase.
  • Sofinnova Investments's biggest Q3 2020 reduction was Coherus Oncology, cutting an estimated $27.9M.
  • Sofinnova Investments fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $84.7M.
  • Sofinnova Investments's ten largest holdings make up 64% of its $1.35B portfolio in Q3 2020.
  • Sofinnova Investments opened 18 new positions and closed 26 in Q3 2020.
  • Sofinnova Investments's portfolio value fell 15% quarter-over-quarter to $1.35B.

Based on Sofinnova Investments's 13F filing for Q3 2020, filed 13 Nov 2020.